Clinical trial
ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study)
NCT05605782 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- September 2, 2021
- Completion date
- July 26, 2033
- Enrollment
- 9,000 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.